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HUMAN	EMBRYONIC	MOSAICISM:	SINGLE-CELL	WHOLE-GENOME	
	
	SEQUENCING	AND	HEPS	CELL	CONVERSTION	
	
AMY	MCLAUGHLIN		ABSTRACT		 Infertility	affects	nearly	10%	of	women	globally,	and	many	of	these	women	seek	Assisted	Reproductive	Technology	(ART)	therapies	(Mascarenhas,	Flaxman,	Boerma,	Vanderpoel,	&	Stevens,	2012).		Despite	the	substantial	clinical	need	for	improvements	in	in	vitro	fertilization,	embryo	implantation,	pregnancy	and	live	birth	rates	following	embryo	transfer	remain	below	50%	(CDC	Division	of	Reproductive	Health,	2017).		This	paper	aims	to	review	the	driving	factors	behind	IVF	failures	and	the	new	technologies	being	utilized	to	improve	IVF	outcomes,	while	also	outlining	novel	experimental	approaches	to	address	these	challenges.	While	morphology,	morphokinetics,	time-lapse	imaging,	and	embryo	biopsy	have	all	been	studied	to	assess	embryo	quality,	no	method	has	proven	to	be	uniquely	effective	in	improving	the	outcomes	of	IVF	treatments.		Single-cell	whole	genome	sequencing	will	be	evaluated	to	determine	if	this	alternative	approach	can	provide	better	information	about	early	embryonic	events	that	may	impede	embryo	viability	in	vivo.		Conversion	of	human	embryonic	stem	cells	(hESCs)	into	human	extended	pluripotent	stem	cells	(hEPS)	will	also	be	undertaken.		Co-culture	of	hEPS	
		 vi 
cells	with	cells	derived	from	human	embryo	trophectoderm	biopsies	will	support	further	investigation	of	early	embryonic	events	at	the	cellular	level,	as	well	as	of	culture	conditions	that	could	facilitate	long-term	culture	of	human	embryonic	trophectoderm	cells.		Ultimately,	the	results	of	both	approaches	will	be	used	to	improve	outcomes	for	patients	seeking	successful	IVF	treatment	and	pregnancy.			 	
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INTRODUCTION			 Infertility	is	the	inability	of	an	organism	to	reproduce	by	natural	means.		As	it	applies	to	human	patients,	infertility	is	an	inability	to	conceive	following	twelve	months	of	unprotected	intercourse.		The	Center	for	Disease	Control	(CDC)	estimates	that	6.7%	of	married	women	in	the	United	States	are	infertile,	up	to	12%	of	women	have	impaired	fecundity,	and	approximately	7.3	million	women	have	sought	treatment	for	infertility	(CDC	“FastStats,”	2017).		The	total	number	of	patients	utilizing	or	who	would	use	Assisted	Reproductive	Technology	(ART)	in	the	U.S.	is	likely	even	higher,	given	that	non-heterosexual	and	male	factor	infertility	patients	are	not	included	in	CDC	estimates.	ART	therapies,	of	which	the	majority	are	in	vitro	fertilization	(IVF)	treatments,	are	also	measured	annually	by	the	CDC	Division	of	Reproductive	Health.		A	total	of	231,936	infertility	cycles	were	completed	by	U.S.	infertility	clinics	in	2015,	an	11%	increase	from	the	previous	year,	where	208,604	cycles	were	performed	(CDC	Division	of	Reproductive	Health,	2017).		The	increase	in	infertility	treatments	is	a	result	of	multiple	factors,	including	social	changes,	such	as	later	age	marriage	and	pregnancy,	as	well	as	technological	advancements	rapidly	improving	the	accessibility	and	efficacy	of	ART	therapies.		Nearly	5	million	children	have	been	born	as	a	result	of	IVF	since	the	first	successful	treatment	in	1980	(Brian,	2013).		Technological	advancements	in	IVF	treatments	have	made	this	possible.				
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Technological	Improvements	in	IVF	Treatments	and	Current	Statistics		Improvements	to	oocyte	retrieval,	oocyte	fertilization,	embryo	culture,	genetic	testing,	and	embryo	transfer	have	transformed	the	way	that	infertility	is	medically	treated.		Transvaginal	sonography	improved	over	the	past	30	years,	making	the	oocyte	retrieval	process	a	non-invasive,	local	anesthesia,	outpatient	procedure	instead	of	an	in-patient,	general	anesthesia	laparoscopy	(Tanbo,	Henriksen,	Magnus,	&	Abyholm,	1988).		The	development	of	Intra-Cytoplasmic	Sperm	Injection	(ICSI)	fertilization	techniques	allows	for	treatment	of	male	factor	infertility,	in	addition	to	female	patient	diagnoses	known	to	require	IVF	therapy,	thereby	increasing	the	number	of	patients	who	are	able	to	benefit	from	ART	therapies	(Pan,	Hockenberry,	Kirby,	&	Lipshultz,	2018;	CDC	Division	of	Reproductive	Health,	2017;	Figure	1).		Improvements	have	also	been	made	inside	the	laboratory.		Researchers	and	physicians	have	shifted	from	mixing	media	in	kitchens	and	clinics	to	developing	commercially	marketed	and	quality-control	produced	embryo	culture	media,	improving	blastocyst	growth	conditions	(Chronopoulou	&	Harper,	2015).		Incubator	technologies	facilitate	blastocyst	growth	by	controlling	O2,	CO2,	and	pH	environmental	conditions,	enabling	better	development	and	allowing	more	time	for	embryo	observation	and	scoring	(Won,	Kim,	Lee,	Kim,	&	Shim,	2018).		In	addition	to	improved	culturing	methods,	cryopreservation	techniques	improved	to	ensure	embryo	viability	safely	and	indefinitely	(Porcu	et	al.,	1997).		Despite	the	dramatic	
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improvement	in	IVF	treatment	technologies	and	protocols,	the	majority	of	IVF	treatment	cycles	are	unsuccessful	in	producing	a	live	birth	(CDC	Division	of	Reproductive	Health,	2017;	Figure	2).	
Figure	1.	ART	Patient	Diagnoses		Female	patients	at	ART	and	IVF	clinics	seek	
treatment	due	to	conditions	that	range	from	age-related	diminished	ovarian	reserve,	
to	physiological	ovulation	dysfunction	and	underlying	hormonal	imbalances.		The	
evolution	of	ICSI	oocyte	fertilization	facilitates	treatment	of	male	factor	infertility.	The	
CDC	reports	that	69%	of	ART	treatments	in	2015	involved	ICSI	fertilized	embryos.	
(CDC	Division	of	Reproductive	Health,	2017)		 	Physicians	initially	addressed	the	low	implantation	and	low	live	birth	rate	of	IVF	procedures	(Figure	2)	by	transferring	multiple	embryos	to	the	female	patient,	increasing	the	likelihood	that	at	least	one	embryo	would	implant	and	reach	a	full-term	pregnancy.			
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Figure	2.	Outcomes	of	ART	Cycles	Using	Fresh	Nondonor	Eggs	or	Embryos,	by	
Stage	and	Age	Group,	2015		Outcomes	of	ART	cycles	completed	at	US	clinics	are	
collected	and	verified	over	the	course	of	two	years	by	the	CDC.		Data	collected	from	
each	cycle	is	not	representative	of	the	number	of	patients	accessing	ART	treatment	in	
the	US,	given	that	many	patients	will	undergo	multiple	cycles.		The	number	of	embryos	
transferred	per	cycle	ranges	from	1-3,	with	the	average	number	of	embryos	increasing	
with	female	patient	age	(Table	1).		As	demonstrated	by	the	low	likelihood	of	cycle	
success,	even	in	the	youngest	patients,	there	is	a	significant	clinical	need	for	
determining	the	likelihood	of	embryo	implantation	before	embryo	transfer.	(CDC	
Division	of	Reproductive	Health,	2017)	
	
	However,	transferring	multiple	embryos	(Table	1)	significantly	increases	the	prevalence	of	a	multiple	pregnancy.		Multiple	pregnancies	lead	to	significant	health	risks	for	both	the	mother	and	fetus	including	low	birth	weight,	increased	infant	mortality,	increased	still	birth	rate,	maternal	high	blood	pressure,	and	other	maternal	complications	(Elster,	2000).			
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Table	1.	Average	Number	of	Embryos	Transferred,	by	Age	of	Patient	and	
Treatment	Protocol,	2015		Patients	undergo	either	fresh	or	frozen	embryo	transfer,	
but	not	both.		There	is	a	positive	correlation	between	the	number	of	embryos	
transferred	and	maternal	age,	with	the	number	of	embryos	transferred	increasing	
with	maternal	age	due	to	lower	rates	of	embryo	implantation	in	older	women.		The	
lower	number	of	frozen	embryos	transferred	reflects	an	increase	in	the	utilization	of	
embryo	selection	and	use	of	SET	following	embryo	scoring,	PGD,	and	PGS	testing.	(CDC	
Division	of	Reproductive	Health,	2017)	
Age	of	Patient	 Average	Number	of	Fresh	Embryos	Transferred	
Average	Number	of	Frozen	
Embryos	Transferred	Under	35	 1.6	 1.5	35-37	 1.8	 1.4	38-40	 2.1	 1.5	41-42	 2.5	 1.6	43-44	 2.6	 1.7	Over	44	 2.4	 1.8		
Given	the	significant	health	risks,	the	American	Society	for	Reproductive	Medicine	(ASRM)	and	the	Society	for	Assisted	Reproductive	Technologies	(SART)	established	physician	guidelines	for	Single	Embryo	Transfer	(SET),	detailing	the	risks	of	multiple	pregnancies	and	the	improved	clinical	outcomes	for	SET	in	patients	under	35	years	old	(American	Society	for	Reproductive	Medicine	&	Practice	Committee	of	the	Society	for	Assisted	Reproductive	Technology,	2017).		SET	reduces	the	health	risks	of	multiple	pregnancies,	but	simultaneously		increases	the	risk	of	embryo	non-implantation,	and	thus,	IVF	cycle	failure.		Due	to	the	lack	of	embryo	implantation	post-transfer,	female	patients	are	likely	to	undergo	multiple	IVF	cycles	before	producing	a	child.		Multiple	IVF	cycles	can	present	a	large	emotional,	psychological	and	physical	burden	to	both	the	patient	and	partner.		These	limitations	and	restrictions	on	IVF	treatment	leave	researchers	and	clinicians	with	a	
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need	for	innovative	and	novel	solutions	to	improve	embryo	selection	and	increase	live	birth	rates.	
DNA	sequencing	and	bioinformatics	have	also	begun	to	play	a	role	in	IVF	treatments	through	pre-implantation	genetic	diagnosis	and	screening	(PGD	and	PGS).		The	first	child	born	following	a	genetically-tested	human	embryo	biopsy	occurred	in	1990	to	prevent	the	transmission	of	adrenoleukodystrophy	to	male	offspring	(Handyside,	Kontogianni,	Hardy,	&	Winston,	1990).		These	insights	and	developments	triggered	new	methods	for	assuring	quality	controls	for	embryo	implantations.		Improvements	in	cryopreservation		in	combination	with	morphological	grading,	time-lapse	imaging,	and		faster,	cheaper	and	more	accurate	genetic	testing	techniques	made	embryonic	scoring,	PGD,	and	PGS	testing	accessible	to	couples	with	a	known	genetic	condition	or	age-related	genetic	risk	factors	(Vermeesch,	Voet,	&	Devriendt,	2016).						
Embryo	Selection	Methods		 The	most	critical	challenge	is	determining	an	efficient	embryo	selection	process	that	correlates	with	clinical	success	to	reduce	the	number	of	embryos	transferred	and	minimize	the	number	of	IVF	cycles	per	patient.		Several	approaches	have	been	investigated	to	address	embryo	selection.		First,	embryologists	have	developed	a	scoring	system	to	grade	the	morphokinetics,	morphology,	and	timeline	
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of	embryo	development	while	observing	embryos	in	in	vitro	culture.		Scoring	systems	can	vary	based	on	the	embryologist	and	physician	involved	with	the	IVF	treatment,	however	several	are	endorsed	by	SART	and	appear	prominently	in	embryo	selection	research	(Table	1;	Table	2;	Table	3).		Better	clinical	outcomes	for	patients	under	35	years	old	have	been	observed	following	selection	of	embryos	displaying	improved	morphological	characteristics,	resulting	in	increased	implantation,	pregnancy,	and	live	birth	rates	(Desai	et	al.,	2014;	Forman,	2017;	Gardner,	Lane,	Stevens,	Schlenker,	&	Schoolcraft,	2000;	Heitmann,	Hill,	Richter,	DeCherney,	&	Widra,	2013;	Irani	et	al.,	2017;	Matsuura	et	al.,	2010;	Nasiri	&	Eftekhari-Yazdi,	2015;	Richardson	et	al.,	2015,	2015).		However,	the	success	of	these	measurements	still	leaves	area	for	improvement.		For	female	patients	over	35	years	old,	morphological	scoring	systems	alone	do	not	display	the	same	improved	implantation	rates	(Keltz	et	al.,	2013).	
Table	2.	SART	Grading	System		The	Society	for	Assisted	Reproductive	Technology	
methodology	for	scoring	embryos	during	development,	based	on	developmental	stage.	
(Heitmann	et	al.,	2013;	Racowsky	et	al.,	2010)	
Growth	Phase	 Overall	Grade	 Stage	
Cleavage	 Good,	Fair,	Poor	 Cell	Number:	1-8+	Fragmentation:	0%,	<10%,	11-25%,	>25%	Symmetry:	Perfect,	Moderately,	Asymmetric,	Severely	Asymmetric	
Morula	 Good,	Fair,	Poor	 Compaction:	Complete,	Incomplete	Fragmentation:	0%,	<10%,	11-25%,	>25%	
Blastocyst	 Good,	Fair,	Poor	 Expansion:	Early,	Expanding,	Expanded,	Hatched	Inner	Cell	Mass:	Good,	Fair,	Poor	Trophectoderm:	Good,	Fair,	Poor	
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Table	3.	Day	5	Embryo	Scoring,	Gardner	and	Schoolcraft		Embryo	scoring	at	day	
five	of	embryo	development	based	on	the	degree	of	blastocyst	development	and	
hatching	of	the	zona	pellucida.	(Gardner	et	al.,	2000;	Heitmann	et	al.,	2013;	Z.	Yang	et	
al.,	2012)	
Score	 Degree	of	Expansion	/	Hatching	Status	1	 Early	blastocyst	with	a	blastocoel	that	is	less	than	half	of	the	volume	of	the	embryo	2	 Blastocyst	with	a	blastocoel	that	is	half	of	or	greater	than	half	of	the	volume	of	the	embryo	3	 A	full	blastocyst	with	a	blastocoel	completely	filling	the	embryo		4	 An	expanded	blastocyst	with	a	blastocoel	volume	larger	than	that	of	the	early	embryo,	with	a	thinning	zona	5	 A	hatching	blastocyst	with	the	trophectoderm	starting	to	herniate	through	the	zona	6	 A	hatched	blastocyst	in	which	the	blastocyst	has	completely	escaped	the	zona	
	
	
Table	4.	SART	Grade	According	to	Embryology	Grading	System		Scoring	system	
used	by	embryologists	to	determine	high	quality	embryos	for	transfer.		Embryos	are	
given	a	two-letter	score	in	which	the	first	letter	of	the	score	corresponds	with	the	
quality	of	the	ICM,	while	the	second	letter	corresponds	with	the	quality	of	the	TE	cell	
layers.	(Heitmann	et	al.,	2013)	
SART	Grade	 ICM	Grade	 Quality	of	ICM	 TE	Grade	 Quality	of	TE	
Good	 A	 Many	cells,	tightly	packed	 A	 Many	cells	forming	a	cohesive	layer	Fair	 B	 Several	cells,	loosely	grouped	 B	 Few	cells	forming	a	loose	epithelium	Poor	 C	 Very	few	cells	 C	 Very	few,	large	cells	
		 Second,	continuous,	time-lapse	monitoring	of	embryo	growth	is		another	technique	being	assessed	to	enhance	embryo	visualization	and	scoring	to	determine	embryo	quality	(Faramarzi,	Khalili,	Micara,	&	Agha-Rahimi,	2017;	Racowsky,	
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Kovacs,	&	Martins,	2015).		Cameras	are	now	able	to	collect	images	over	the	course	of	embryonic	development	without	the	need	to	remove	the	embryo	from	the	incubator.	Maintaining	the	environmental	conditions	reduces	the	likelihood	of	disrupting	oxygen,	carbon	dioxide,	and	pH	balance	in	growing	conditions	(Faramarzi	et	al.,	2017).		The	images	are	then	used	to	inform	quality	grading,	with	faster	growing	and	more	uniform	embryos	scoring	higher	on	morphology	criteria	(Finn,	Scott,	O’Leary,	Davies,	&	Hill,	2010;	Kaser	&	Racowsky,	2014).	The	non-invasive	technique	could	be	a	useful	tool	in	analyzing	and	studying	embryonic	growth	over	time.	However,	studies	have	demonstrated	that	there	is	only	a	minimal	positive	correlation	with	uniform	embryo	morphology	and	likelihood	of	IVF	cycle	success	(Desai	et	al.,	2014;	Kaser	&	Racowsky,	2014;	Racowsky	et	al.,	2015).		Alternative	methods	must	be	further	investigated	to	markedly	decrease	the	rates	of	IVF	failure.		Discovering	more	specific	markers,	including	genetic	and	transcriptomic	sequencing,	has	become	the	frontier	for	examining	embryological	efficacy.		 Researchers	and	clinicians	have	turned	to	the	genetic	expression	of	early	embryos	to	decipher	the	root	cause	of	IVF	failures.		The	improvements	in	embryo	culture	techniques	and	the	rapidity	of	genetic	sequencing	facilitates	ongoing	investigation	of	genetic	expression	in	the	developing	embryo	(Vermeesch	et	al.,	2016;	Petropoulos	et	al.,	2016).		Embryos	undergoing	biopsies	of	the	polar	body,	blastomeres,	and	blastocysts	can	all	result	in	viable	embryos,	pregnancy,	and	live	births.		Genetic	information	collected	from	these	cells	has	been	demonstrated	to	be	
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effective	in	selecting	embryos	to	prevent	the	transmission	of	genetic	defects	from	parent	to	child	(Simpson,	2010;	Verlinsky	et	al.,	1990;	Vermeesch	et	al.,	2016).		As	biopsy	collection	and	genetic	analysis	have	become	more	prevalent,	an	immense	amount	of	data	has	been	collected	but	is	still	poorly	understood.		Efforts	are	expanding	to	determine	if	altered	gene	expression	during	development	of	the	embryo	can	elucidate	insights	into	the	implantation	efficiency	of	a	transplanted	embryo.		
Human	Embryonic	Mosaicism		 During	the	first	few	days	of	embryonic	development,	the	embryo	undergoes	rapid	cell	division,	and	cell	differentiation	into	trophectoderm,	primitive	endoderm,	and	inner	cell	mass	pluripotent	cells	(Maxwell	et	al.,	2016).		Genetic	sequencing	of	cells	retrieved	through	embryo	biopsies	reveals	that	even	at	this	early	stage,	these	cells	can	express	different	and,	or	abnormal	genetic	profiles	including	chromosome	copy	number	or	cross-over	errors.		Aneuploidy,	or	the	presence	of	an	abnormal	chromosome	profile	in	a	cell,	can	exist	in	one	or	more	cells	in	human	embryos.	Human	embryonic	mosaicism,	or	the	difference	in	and	distribution	of	genetic	expression	of	individual	cells	within	an	embryo,	raises	an	area	of	concern	and	a	potential	area	for	discovering	the	cellular	mechanisms	underlying	IVF	failure.			At	the	early	stages	of	division,	errors	can	occur	during	both	mitosis	and	meiosis.		Meiotic	errors	can	occur	when	the	oocyte	completes	both	meiosis	I	and	
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meiosis	II.		More	than	75%	of	the	genetic	errors	caused	during	meiosis	occur	during	meiosis	I,	while	the	other	25%	of	errors	occur	during	meiosis	II	(Capalbo	&	Rienzi,	2017;	Chiang,	Schultz,	&	Lampson,	2012;	May	et	al.,	1990).		Meiotic	errors	persist	more	uniformly	across	the	embryo,	and	are	unlikely	to	be	down-regulated	or	selected	against	(Capalbo	&	Rienzi,	2017).		Genetic	replication	proceeds	rapidly	following	fertilization,	with	an	upregulation	in	proteins	that	facilitate	cell	replication	and	a	low	level	of	checkpoint	protein	expression	(Capalbo	&	Rienzi,	2017).		The	lower	levels	of	checkpoint	proteins	that	would	slow	the	replication	cycles	and	confirm	accurate	DNA	replication	allow	errors	in	genetic	replication	to	persist	in	some	or	all	of	the	replicating	cells.		These	errors	can	appear	in	clusters	within	the	embryo	or	more	evenly	distributed	between	trophectoderm,	primitive	endoderm,	and	inner	cell	mass	regions	depending	on	the	point	in	development	at	which	the	error	in	mitosis	occurs	(Scott	et	al.,	2012).		Data	suggests	that	after	day	three	of	development,	more	than	half	of	human	embryos	contain	at	least	one	aneuploid	cell	(McCoy	et	al.,	2015).		Given	the	high	frequency	of	both	meiotic	and	mitotic	genetic	replication	errors,	it	is	unsurprising	that	research	has	focused	on	determining	the	degree	to	which	genetic	errors	contribute	to	embryonic	viability.		 Several	studies	have	demonstrated	that	the	percentage	of	aneuploid	cells	in	a	developing	embryo	has	a	clinical	correlation	with	the	likelihood	of	embryo	implantation	following	transfer	to	the	female	uterus.		Embryos	containing	a		greater	percentage	of	aneuploid	cells	have	the	lowest	probability	of	implantation,	and	the	likelihood	of	producing	an	aneuploid	embryo	increases	with	female	patient	age	
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(Fragouli	et	al.,	2017;	Hassold	&	Hunt,	2001;	Weissman	et	al.,	2017).		As	a	result,	the	utilization	of	Pre-Implantation	Genetic	Diagnosis	(PGD)	and	Pre-Implantation	Genetic	Screening	(PGS)	has	increased	from	3%	to	5%	of	all	cycles	from	2014	to	2015	(CDC	Division	of	Reproductive	Health,	2017),	and	has	likely	increased	further	in	frequency	of	use	by	ART	physicians	over	the	past	two	years	(Fragouli	et	al.,	2017).		 Improvements	in	cryopreservation	techniques,	in	combination	with	the	speed	of	genetic	testing	methods,	have	increased	the	amount	of	time	available	to	physicians	and	embryologists	from	days	to	weeks	to	evaluate	an	embryo.		A	larger	time	window	to	freeze	the	embryo,	evaluate	an	embryo	biopsy,	and	analyze	the	results	ensures	a	better	selection	profile	for	physicians	and	embryologists	to	make	informed	decisions	about	the	course	of	treatment	(Kuwayama,	Vajta,	Kato,	&	Leibo,	2005;	Sachdeva,	Discutido,	Albuz,	Almekosh,	&	Peramo,	2017).		Yet,	the	increase	in	time	for	testing	has	only	resulted	in	physicians	being	inundated	with	data	that	provides	no	clear	direction	for	clinical	decision-making	(Weissman	et	al.,	2017).		It	is	imperative	that	results	of	genetic	analyses	provide	more	clarity	about	the	probability	of	embryo	implantation	success	(Capalbo	&	Rienzi,	2017).			Previous	findings	have	determined	that	combining	genetic	sequencing	with	morphological	grading	provides	a	better	method	to	select	embryos	for	implantation	(Keltz	et	al.,	2013;	Maxwell	et	al.,	2016).		In	addition,	blastocyst	biopsies	at	day	five	have	proven	to	be	more	representative	of	overall	embryonic	health	than	biopsies	of	cleavage	state,	day	three	embryos	(Fragouli	et	al.,	2017;	Keltz	et	al.,	2013;	McCoy	et	al.,	2015;	Won	et	al.,	2018).		Later	biopsies	also	facilitate	the	collection	of	a	greater	
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number	of	trophectoderm	cells.		Sometimes	found	in	clusters	within	the	day	five	blastocysts,	aneuploid	cells	are	predominantly	distributed	between	the	trophectoderm	and	the	inner	cell	mass.		This	leaves	into	question	the	degree	to	which	blastocyst	biopsies	can	represent	the	overall	aneuploidy	status	of	an	embryo	(Capalbo	&	Rienzi,	2017).		The	time	table	for	the	returning	sequencing	data	to	physicians	can	be	both	costly	and	long.		Once	biopsied,	the	cell	DNA	must	be	amplified,	then	sequenced	and	analyzed	by	a	genomics	platform.		Therefore,	the	careful	selection	of	cells	from	the	biopsy	is	imperative	to	ensure	the	most	accurate	and	useful	data	is	received	and	provided	to	physicians	acting	as	decision	makers	in	the	clinic.	The	amplification	technique	utilized,	and	genetic	platform	employed	require	further	investigation	to	improve	the	reliability	of	PGD	and	PGS	embryonic	testing	in	the	clinic.			 	
Genetic	Sequencing	and	Application	for	Human	Embryo	Biopsies	Cryopreservation	of	human	embryos	has	enabled	researchers	to	test	different	sequencing	techniques	for	a	small	number	of	cells	retrieved	from	a	biopsy.		Fluorescence	in	situ	hybridization	(FISH),	array	comparative	genomic	hybridization	(aCGH),	and	single	nucleotide	polymorphism	(SNP)	arrays	have	all	be	studied,	but	none	have	proven	to	be	exclusively	effective	(Capalbo	&	Rienzi,	2017;	Johnson	et	al.,	2010;	Keltz	et	al.,	2013;	Kushnir,	Darmon,	Barad,	&	Gleicher,	2018;	Matsuura	et	al.,	2010;	Scott	et	al.,	2012;	Weissman	et	al.,	2017;	Won	et	al.,	2018).	
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FISH,	aCGH,	and	SNP	arrays	all	require	gene	amplification	in	order	to	obtain	enough	volume	of	genetic	material	to	yield	detectable	results.		Quantitative	polymerase	chain	reaction	(qPCR)	is	typically	used	for	rapid	genetic	amplification	before	genetic	analysis.		However,	qPCR	utilizes	primers	that	can	anneal	to	regions	of	the	chromosome	with	different	levels	of	specificity,	resulting	in	an	imbalanced	amplification	of	different	chromosome	regions.		Disproportionate	amplification	has	a	reduced	effect	when	dealing	with	larger	cell	populations,	but	could	drastically	distort	genetic	data	collection	when	dealing	with	the	limited	amount	of	genetic	material	present	in	the	5-10	cells	of	human	embryo	biopsies.	FISH	has	confirmed	aneuploid	cells	in	embryos	using	fluorescently-tagged	primers	that	anneal	to	specific	regions	of	the	chromosome	(Capalbo	&	Rienzi,	2017;	Vermeesch	et	al.,	2016;	Weissman	et	al.,	2017).		Utilization	of	FISH	can	be	limited	due	to	the	failure	of	primers	to	hybridize	with	the	target	chromosome,	primers	annealing	to	overlapping	regions	of	the	chromosome,	and	signal	splitting	(Capalbo	&	Rienzi,	2017;	Simpson,	2010;	Weissman	et	al.,	2017).		FISH	is	also	unable	to	quantify	the	copy	number	of	each	chromosome	therefore	unlikely	to	identify	monosomy	and	trisomy	meiotic	errors	(Scott	et	al.,	2012).		For	these	reasons,	aCGH	and	SNP	arrays	are	alternative	methods	for	genetic	data	collection	(Munné	&	Wells,	2017;	Won	et	al.,	2018).	Next	generation	sequencing	(NGS),	aCGH,	and	SNP	arrays	are	all	used	clinically	for	human	embryo	biopsies	to	detect	chromosome	copy	number	and	mitotic	error	aneuploidy	(Capalbo	&	Rienzi,	2017;	Johnson	et	al.,	2010;	Munné	&	
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Wells,	2017;	Petropoulos	et	al.,	2016;	Sachdeva	et	al.,	2017;	Scott	et	al.,	2012,	2013;	Simpson,	2010;	Weissman	et	al.,	2017;	Won	et	al.,	2018).		Despite	their	frequent	use,	these	techniques	are	unable	to	sequence	individual	cells,	but	must	instead	involve	the	combination	of	genetic	material	from	multiple	cells	for	one	analysis	(Sachdeva	et	al.,	2017).		Although	some	cell-cell	variation	can	be	detected,	none	of	these	techniques	are	able	to	provide	a	detailed	picture	of	individual	cell	level	variation	(Munné	&	Wells,	2017).		NGS,	aCGH,	and	SNP	arrays	therefore	can	provide	an	estimate	of	the	percentage	of	aneuploid	cells	in	a	given	sample,	which	may	or	may	not	be	representative	of	overall	embryo	viability.	When	analyzing	embryo	biopsies	in	combination	with	clinical	data,	retroactive	studies	demonstrated	a	correlation	between	the	level	of	aneuploidy	and	clinical	outcomes.		Embryos	that	have	fewer	than	50%	aneuploid	cells	have	a	higher	likelihood	of	embryo	implantation	and	live	births	(Capalbo	&	Rienzi,	2017;	Maxwell	et	al.,	2016;	Taylor	et	al.,	2014).		Despite	promising	data,	the	medical	and	research	communities	have	yet	to	reach	agreement	about	the	threshold	of	aneuploidy	or	number	of	affected	cells	required	to	designate	an	embryo	as	aneuploid	(Munné	&	Wells,	2017).		As	genetic	testing	has	become	faster	and	more	easily	accessible,	many	physicians	are	provided	information	about	embryo	mosaicism	in	genetic	reports,	but	do	not	view	that	information	as	clinically	actionable	(Capalbo	&	Rienzi,	2017;	Munné	&	Wells,	2017).		For	patients	that	have	multiple	embryos,	of	which	more	than	one	are	designated	euploid	in	genetic	reports,	physicians	will	select	the	euploid	embryos	for	transfer.		The	decision	criteria	become	more	opaque	when	there	are	
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multiple	embryos	that	have	an	intermediate	level	of	either	meiotically	or	mitotically	derived	mosaicism.		 The	aims	of	pursuing	single-cell	whole	genome	sequencing	for	trophectoderm	biopsies	is	to	investigate	and	potentially	address	these	problems:	the	requirement	of	genetic	amplification	for	current	genetic	sequencing	methods,	data	collection	and	visualization	of	mosaicism	at	the	resolution	of	a	single	cell,	and	a	validation	of	a	method	for	better	clinical	pre-implantation	screening	of	embryos	most	likely	to	result	in	a	successful	pregnancy.				
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METHODS		
Single-Cell	Whole	Genome	Sequencing	of	Human	Embryo	Trophectoderm	
Biopsies			 Human	embryos	and	trophectoderm	cell	biopsies	were	donated	and	consented	to	research	collected	from	Boston	IVF.		All	biologic	material	was	de-identified	and	transferred	to	Harvard	Stem	Cell	Institute.		Robotic	micromanipulation	technology,	in	partnership	with	Massachusetts	Institute	of	Technology,	used	to	isolate	individual	cells.		To	address	biases	associated	with	genome	amplification,	the	outcomes	of	three	techniques,	single-cell	multiple	displacement	amplification	(SCMDA)	(Dong	et	al.,	2017),	multiple	displacement	amplification	(MDA)	(Gawad,	Koh,	&	Quake,	2016),	and	multiple	annealing	and	looping	based	amplification	cycles	(MALBAC)	(Zong,	Lu,	Chapman,	&	Xie,	2012)	were	compared	using	human	embryonic	stem	cells	of	known	genetic	composition.		Collaboration	with	the	McCarroll	and	Love	laboratories	within	Harvard	Stem	Cell	Institute	assisted	with	interpretation	of	single	cell	sequencing	data	from	NGS	platforms.		 Cells	from	human	embryo	biopsies	were	sequenced	in	parallel	with	the	remaining	cells	of	the	embryo.		Results	of	the	genetic	tests	of	both	samples	was	compared	to	determine	how	representative	a	biopsy	is	when	compared	to	the	cells	of	the	embryo	in	its	entirety.		If	possible,	location	of	each	cell	was	tracked	to	
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determine	the	distribution	of	mosaicism	within	the	embryo.		Sensitivity	of	each	amplification	method	in	detecting	genetic	variants	was	also	assessed.	(Figure	3)	
Figure	3.	Overview	of	Experimental	Strategy	for	Single-Cell	Whole	Genome	
Sequencing	of	Human	Embryo	Trophectoderm	Biopsies	(a)	In	vitro	culture	of	
fertilized	human	eggs	to	the	blastocyst	stage.	(b)	Trophectoderm	biopsy	(10	cells).	(c)	
Whole	genome	amplification	of	genomic	DNA.	(d)	Single	cell	whole	genome/genome	
sequencing.	(e)	Detection	of	variants	(copy	number	variants,	single	nucleotide	
changes)	in	genomic	sequence	using	bioinformatics	tools.	(f)	Analysis	of	mosaicism	in	
inner	cell	mass	and	trophectoderm.		
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hESC	to	hEPS	Cell	Conversion		 Protocol	of	hESC	to	hEPS	conversion	modified	from	(Y.	Yang	et	al.,	2017).		Three	cell	lines	(H1,	H9,	and	wiBR3)	were	obtained	from	Harvard	Stem	Cell	Institute	for	conversion.		H1,	H9	and	wiBR3	cell	lines	were	thawed	simultaneously.		Cells	were	cultured	at	5%	CO2,	37°C	on	mouse	embryonic	fibroblast	(MEF)	feeder	cells.		All	three	cells	lines	were	cultured	in	hESC	primed	media	comprised	of	DMEM/F12	supplemented	with	20%	knockout	serum	replacement	(KSR),	1%	GlutaMAX,	1%	nonessential	amino	acids,	0.1	mM	b-mercaptoethanol,	and	4-10	ng/ml	bFGF.		Media	was	mixed	to	include	the	following	volumes:	400	mL	DMEM/F12,	100	mL	KSR,	5	mL	GlutaMAX,	5	mL	of	nonessential	amino	acids,	900	µL	b-mercaptoethanol,	and	250	µL	bFGF.		Cell	lines	were	cultured	for	twelve	days	and	passaged	twice	before	switching	to	complete	hEPS	media.	Cells	were	switched	to	hEPS	complete	media	two	days	following	the	second	passage	of	primed	hESCs,	and	on	day	12	of	culture.		Complete	hEPS	media	was	comprised	of	a	base	hEPS	media	prepared	with	240	mL	of	DMEM/F12,	240	mL	Neurobasal,	2.5	mL	N2	supplement,	5	mL	B27	supplement,	1%	GlutaMAX,	1%	nonessential	amino	acids,	0.1	mM	b-mercaptoethanol,	and	5%	KSR.		Penicillin	or	Streptomycin	as	recommended	by	(Y.	Yang	et	al.,	2017)	were	omitted.		50	mL	aliquots	of	base	hEPS	media	was	supplemented	with	the	following	small	molecules	and	cytokines:	5	µL	LIF	at	a	concentration	of	10	ng/mL,	5	µL	of	3	mM	CHIR99021,	5	
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µL	of	2	mM	S-+-dimethindene	maleate,	5	µL	of	2	mM	minocycline	hydrochloride,	5	
µL	of	0.5-1	mM	IWR-endo,	and	10	µL	of	2	mM	Y-27632	inhibitor.			MEF	feeder	cells	were	plated	one	day	before	each	passage,	and	washed	with	PBS	on	day	of	passage.		Cells	were	digested	and	removed	from	plates	using	300	µL	TripLE	per	well	in	a	6-well	plate,	then	returned	to	in	an	incubator	at	5%	CO2	and	37°C	for	3-5	minutes.		Cells	were	washed	in	50	mL	of	DMEM/F12,	and	spun	down	at	1,200	rpm	at	room	temperature	for	five	minutes.		Cells	were	split	at	ratios	ranging	from	1:3-1:15	depending	on	cell	line	growth	rates	and	cultured	in	5%	CO2	and	37°C	(Table	5).		All	three	cell	lines	were	passaged	six	times	before	storing	at	-80°C.	
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RESULTS		
Single-Cell	Whole	Genome	Sequencing	of	Human	Embryo	Trophectoderm	
Biopsies		 The	Single-Cell	Whole	Genome	Sequencing	of	Human	Embryo	Trophectoderm	Biopsies	protocol	was	approved	by	the	Harvard	Institutional	Review	Board,	(IRB)	Harvard	University	Embryonic	Stem	Cell	Research	Oversight	(ESCRO)	committee,	Boston	IVF,	and	the	Eggan	Laboratory.		A	“Scientific	Projects	to	Accelerate	Research	and	Collaboration”	(SPARC)	grant	was	awarded	to	the	project	by	the	Broad	Institute	to	begin	sourcing	supplies	and	establish	a	pipeline	for	source	biological	material.		
hESC	to	hEPS	Cell	Conversion		hESC	to	hEPS	conversion	of	three	human	cell	lines	was	successful	(Table	5).		Growth	of	each	cell	line	in	the	EPS	media	progressed	at	different	rates,	demonstrating	a	variability	in	ability	to	thrive	in	hEPS	media	and	growth	conditions.		All	three	cell	lines	converted	can	be	used	for	co-culture	of	human	embryo	trophectoderm	biopsy	to	stabilize	trophectoderm	cell	growth	to	produce	the	increased	volume	of	genetic	material	required	for	single-cell	whole	genome	sequencing.		Individual	cell	line	response	to	hEPS	media	detailed	in	Table	5.	
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Table	5.	hESC	to	hEPS	Conversion	Results	Three	hESC	lines	obtained	from	Harvard	
Stem	Cell	Institute	were	converted	to	hEPS	cells.		Passage	1	refers	to	second	passage	of	
cell	lines	following	thaw	and	before	conversion	to	hEPS	media.		The	switch	to	hEPS	
media	was	made	two	days	following	Passage	1	and	four	days	before	Passage	2.		hEPS	
conversion	was	successful	and	cells	will	be	co-cultured	with	cells	collected	from	human	
embryo	biopsy.		 	 hESC	Lines	Undergoing	Conversion	
H1	 H9	 wiBR3	
Passage	1	 Cells	split	at	a	1:10	ratio	following	5	days	of	culture	in	primed	hESC	media.		Media	switched	to	hEPS	two	days	after	passage.	
Passage	2	 Cells	passaged	after	6	days	at	1:5	and	1:1.67	ratios	 Cells	passaged	after	6	days	at	1:2	ratio	 Cells	passaged	after	6	days	at	1:5	and	1:3	ratios	
Passage	3	 Cells	passaged	after	7	days	at	1:3	and	1:5	ratios	 Cells	passaged	after	6	days	at	1:10	and	1:15	ratios	 Cells	passaged	after	7	days	at	1:3	and	1:5	ratios	
Passage	4	 Cells	passaged	after	3	days	at	1:10	and	1:15	ratios	 Cells	passaged	after	4	days	at	1:10	and	1:15	ratios	 Cells	passaged	after	4	days	at	1:10	and	1:15	ratios	
Passage	5	 Cells	passaged	after	7	days	at	1:10	and	1:15	ratios	 Cells	passaged	after	6	days	at	1:10	and	1:15	ratios	 Cells	passaged	after	6	days	at	1:10	and	1:15	ratios	
Passage	6	 Cells	passaged	after	6	days	to	100	x	20mm	plates	for	storage	preparation	
Storage	 All	three	cell	lines	were	removed	from	plates	and	prepared	for	storage	at	-80°C.		hEPS	cells	to	be	used	for	co-culture	with	cells	from	human	embryo	TE	biopsies	in	preparation	for	single-cell	whole	genome	sequencing.		
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DISCUSSION		 Study	of	early	embryonic	events	is	limited	due	to	a	scarcity	of	biological	materials,	and	legal	and	ethical	restrictions	on	embryo	research.		Research	is	limited	to	the	embryos	that	are	marked	as	morphologically	abnormal,	biopsied	frozen	embryos	that	have	resulted	in	an	aneuploid	genetic	test,	embryos	discarded	on	day	of	transfer,	and	frozen	embryos	that	have	been	donated	following	successful	IVF	treatment.		The	majority	of	these	embryos	donated	to	research	present	initially	with	genetic	abnormalities,	and	the	information	gathered	from	these	samples	should	be	accounted	for	accordingly.		Despite	inherent	challenges,	both	single-cell	whole	genome	sequencing	of	trophectoderm	biopsies	and	hEPS	cell	cultures	could	provide	further	insight	into	how	genetic	aneuploidies	can	affect	embryo	implantation,	cell	fate	decisions,	and	fetal	viability.	Single-cell	whole	genome	sequencing	of	human	embryos	opens	the	door	for	an	alternative	method	of	discerning	the	impact	of	early	meiotic	and	mitotic	genetic	errors.		Deciphering	the	derivation	of	genetic	errors	could	inform	the	determination	of	embryonic	viability.		Little	research	has	been	done	using	NGS	to	visualize	genetic	errors	at	the	level	of	a	single-cell	due	to	challenges	with	genetic	sequencing	techniques,	and	physical	manipulation	of	individual	cells.		Understanding	genetic	variation	at	the	individual	cell	level	could	provide	additional	insight,	not	only	into	the	drivers	of	implantation	failure,	but	also	to	the	merits	and	phenotypic	effects	of	genetic	diversity.		Over-selection	of	embryos	could	result	in	screening	out	embryos	
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that	could	produce	both	genetically	and	phenotypically	normal	offspring.		Studying	the	relationship	between	small-scale	genetic	variation	and	the	success	of	IVF	therapies	could	provide	increased	clarity	for	physicians	with	respect	to	genetic	testing	and	embryo	selection,	while	also	maintaining	genetic	diversity	in	the	population.		In	vitro	models	like	hEPS	cells	can	be	used	to	study	the	cellular	events	that	can	better	inform	genetic	testing	procedures.	Successful	conversion	of	hESC	to	hEPS	cells	creates	a	model	for	the	study	of	early	human	embryonic	events	in	vitro.		hEPS	cells	have	the	ability	to	differentiate	into	trophectoderm,	inner	cell	mass,	and	primitive	endoderm	cell	types	–	the	first	major	hESC	differentiation	point	in	the	development	of	the	human	embryo.		Preliminary	research	into	genetic	expression	patterns	at	this	early	stage	has	indicated	variations	in	genetic	expression	could	support	or	deter	implantation	events	(Petropoulos	et	al.,	2016).		hEPS	cells	have	also	been	co-cultured	with	hESC	cells	on	a	3D	extracellular	matrices,	self-assembling	into	an	early	embryonic	structure,	facilitating	the	visualization	of	early	implantation	checkpoints	(Shahbazi	et	al.,	2016).		It	is	possible	that	hEPS	cells	are	not	identical	to	pre-implantation	cells	in	the	human	embryo,	and	additional	research	is	required	to	determine	whether	genetic	signaling	from	these	cells	could	vary	from	early	human	embryonic	derived	cell	lines.		Detailed	study	of	hEPS	cells	using	RNA	sequencing,	proteomics,	and	metabolomics	could	inform	co-culture	and	embryonic	assembly	research.		Study	of	early	embryonic	differentiation	events	could	help	to	inform	the	study	of	both	
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embryonic	mosaicism	and	of	genetic	testing	to	improve	implantation	outcomes	in	IVF	treatments.			Co-culture	of	trophectoderm	biopsy	cells	with	hEPS	cells	could	create	an	alternative	pathway	for	DNA	amplification.		Currently,	human	trophectoderm	cells	are	unable	to	survive	in	long-term	culture	conditions.		Co-culturing	biopsied	trophectoderm	cells	with	hEPS	cells	of	known	genetic	composition	could	promote	trophectoderm	cell	replication,	amplifying	the	number	of	cells,	and	increasing	NGS	single-cell	whole	genome	sequencing	resolution	of	the	embryo	cell	biopsy.		Additional	hESC	cell	lines	could	also	be	converted	to	hEPS	cells	to	further	refine	growth	conditions	for	hEPS	cells	in	preparation	for	variations	in	co-culture	conditions.		Cells	from	different	trophectoderm	biopsies	could	respond	atypically	in	standardized	culture	conditions,	which	would	require	protocol	adjustment	to	acquire	the	volume	of	DNA	required	for	NGS	analysis.		Most	NGS	platforms	require	hundreds	of	nanograms	to	micrograms	of	input	DNA,	therefore	increasing	the	amount	of	genetic	information	available	could	facilitate	comparison	across	sequencing	platforms	and	standardization	across	IVF	clinics.		Enhancing	and	developing	high-resolution	single	cell	genetic	sequencing	can	help	improve	clinical	decision	making	following	PGD	and	PGS	testing.			As	NGS	testing	becomes	more	widely	utilized	for	applications	in	IVF	and	other	diseases,	costs	will	decrease	such	that	PGD	and	PGS	testing	can	become	standard	of	care	for	IVF	treatments.		The	more	complete	the	picture	available,	protocols	can	be	developed	and	modified	to	create	definitive	screening	criteria	that	
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can	ensure	viable	pregnancies,	but	not	effect	over-selection	or	decreasing	population	genetic	diversity.	PGD	and	PGS	sequencing	of	human	embryo	trophectoderm	biopsies	has	become	simultaneously	more	accessible	and	affordable	to	patients,	while	more	confusing	for	physicians.		The	majority	of	NGS	reports	from	PGD	and	PGS	analyses		will	report	on	the	mosaicism	of	a	sample,	but	there	is	still	disagreement	in	the	medical	community	around	how	to	proceed	with	that	information	(Weissman	et	al.,	2017).		Physicians	generally	agree	that	human	embryos	with	mosaicism	greater	than	50%	are	considered	aneuploid	and	non-transferable,	while	physicians	will	proceed	with	embryos	considered	euploid,	a	mosaicism	less	than	20%.		Consensus	has	yet	to	be	reached	on	embryos	with	mosaicism	between	20-50%,	with	early	results	demonstrating	implantation	is	possible	albeit	at	lower	rates	than	a	euploid	embryo	(Capalbo	&	Rienzi,	2017;	Fragouli	et	al.,	2017;	Maxwell	et	al.,	2016;	Weissman	et	al.,	2017).		Furthermore,	the	trophectoderm	cells	biopsied	from	the	embryo	represent	a	subset	of	the	cells	that	comprise	the	embryo	as	a	whole.		Analysis	of	multiple	biopsies	of	the	same	embryo	demonstrate	that	mosaicism	levels	could	vary	substantially	across	biopsies,	and	the	result	of	a	PGD	or	PGS	test	may	not	be	representative	of	the	overall	health	of	an	embryo	(Kushnir	et	al.,	2018).		There	is	some	evidence	that	shows	that	an	aneuploid	trophectoderm	biopsy	is	indicative	of	overall	embryo	aneuploidy	in	58%	of	embryos	(Munné,	Grifo,	&	Wells,	2016;	Garrisi	et	al.,	2016).		An	inherent	difficulty	of	using	trophectoderm	biopsies	is	that	they	are	cells	that	will	ultimately	comprise	the	placenta	layer,	as	opposed	to	the	inner	cell	
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mass	cells	that	will	develop	into	the	fetus.		Analysis	of	single-cell	whole	genome	genetic	sequencing	data	of	both	trophectoderm	biopsies	and	whole	human	embryos	could	provide	additional	insight	into	the	distribution	of	human	embryonic	mosaicism	and	the	best	protocols	for	PGD	and	PGS	testing.		More	detailed	research	into	specific	protein	level	analysis	or	RNA	sequencing	of	embryos	at	different	developmental	checkpoints	would	also	be	beneficial	to	explore	whether	it	is	possible	to	find	a	genetic	signature	that	could	correspond	directly	to	embryonic	implantation	probability	and	in	utero	embryo	viability.		High-resolution	genetic	sequencing	could	then	be	standardized	to	be	used	as	an	additional	embryo	grade	to	improve	embryo	selection,	and	thus	implantation	outcomes	for	IVF	treatments.	Finally,	increased	efficiency	of	IVF	treatments	to	reduce	costs	and	make	them	more	broadly	available	to	patients	who	require	assistance.		Increased	utilization	could	also	increase	PGD	and	PGS	testing	that	would	increase	the	amount	of	information	available	for	research.		Additional	information	can	be	used	to	inform	the	treatment	process	to	better	serve	all	patients.			Ultimately,	information	sharing	across	countries	and	treatment	centers	could	create	a	standardized	approach	to	genetic	screening.		Currently	there	is	a	lack	of	agreement	across	the	medical	and	research	communities	around	the	standard	of	care	for	IVF	patients	due	to	a	lack	of	basic	science	and	clinical	research	(Weissman	et	al.,	2017).		Standardizing	an	approach	and	creating	consensus	could	drive	improved	outcomes	for	all	IVF	patients.				Agreement	amongst	physicians	would	
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decrease	the	risks	of	multiple	pregnancies,	emotional	and	psychological	trauma,	improve	infant	mortality	and	outcomes	worldwide.	While	enhancing	the	efficacy	of	PGD	and	PGS	testing	of	human	embryos	can	improve	clinical	outcomes,	the	selection	of	embryos	raises	pressing	ethical	questions.		Human	embryonic	mosaicism	can	present	as	a	wide	range	of	genetic	errors	across	the	human	genome.		While	some	chromosome	deletions	or	additions	may	result	in	an	inviable	embryo,	other	genetic	abnormalities	create	viable	embryos	but	with	significant	phenotypic	consequences.		SNPs	and	chromosomal	translocations	may	also	result	in	viable	embryos,	but	could	result	in	increased	genetic	predisposition	to	disease.		It	is	possible	that	a	genetic	signature	of	genetic	replication	errors	could	signal	viability	of	a	human	embryo,	but	viability	must	be	considered	in	parallel	long-term	health	of	the	fetus.		Genetic	counseling	with	both	physicians	and	patients	is	necessary	before	taking	action	in	IVF	decision	making.				
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